In this study, we sought to detect mutations in patients with B-cell NHL and compare mutational status over time using different cytological and histological preparations as the substrate for a customized multiplex mutation assay for the detection of point mutations involving EZH2 and CD79B using the MassARRAY spectrometry platform. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.